Volume 70, Issue 4, Pages (October 2016)

Slides:

Advertisements

Similar presentations

Volume 53, Issue 3, Pages (March 2008)

Advertisements

Volume 55, Issue 1, Pages 1-8 (January 2009)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 4, Pages (October 2010)

Volume 66, Issue 1, Pages (July 2014)

Outcome of Ultrasound-guided Sclerotherapy for Varicose Veins: Medium-term Results Assessed by Ultrasound Surveillance K.A. Myers, D. Jolley, A. Clough,

Testosterone Therapy in Men With Prostate Cancer

Volume 56, Issue 6, Pages (December 2009)

Volume 191, Issue 6, Pages (June 2014)

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Volume 74, Issue 4, Pages (October 2018)

Volume 61, Issue 6, Pages (June 2012)

Volume 53, Issue 4, Pages (April 2008)

Volume 70, Issue 6, Pages (December 2016)

Volume 70, Issue 1, Pages (July 2016)

Control of Prostate Cancer by Transrectal HIFU in 227 Patients

Volume 69, Issue 1, Pages (January 2016)

Volume 65, Issue 5, Pages (May 2014)

Volume 70, Issue 4, Pages (October 2016)

Prostate Cancer Epidemic in Sight?

Volume 52, Issue 4, Pages (October 2007)

Volume 72, Issue 5, Pages (November 2017)

Volume 63, Issue 1, Pages (January 2013)

Volume 68, Issue 5, Pages (November 2015)

Volume 68, Issue 5, Pages (November 2015)

Volume 73, Issue 2, Pages (February 2018)

Volume 67, Issue 3, Pages (March 2015)

Volume 59, Issue 4, Pages (April 2011)

Volume 67, Issue 6, Pages (June 2015)

The association of chronic kidney disease and dialysis treatment with foot ulceration and major amputation Jeroen Otte, MD, MSc, Jaap J. van Netten,

Volume 70, Issue 5, Pages (November 2016)

Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients Timo F.W. Soeterik,

Volume 52, Issue 4, Pages (October 2007)

Prostate Cancer Epidemic in Sight?

Volume 53, Issue 2, Pages (February 2008)

Volume 64, Issue 4, Pages (October 2013)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 61, Issue 6, Pages (June 2012)

Volume 58, Issue 4, Pages (October 2010)

Volume 68, Issue 6, Pages (December 2015)

Volume 53, Issue 6, Pages (June 2008)

Volume 53, Issue 4, Pages (April 2008)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 63, Issue 3, Pages (March 2013)

Volume 71, Issue 1, Pages (January 2017)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Physical Activity and Survival After Prostate Cancer

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 50, Issue 5, Pages (November 2006)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

The association of chronic kidney disease and dialysis treatment with foot ulceration and major amputation Jeroen Otte, MD, MSc, Jaap J. van Netten,

Volume 71, Issue 3, Pages (March 2017)

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer Amar U. Kishan, Rahul.

Long-Term Hormonal Therapy: Who Would Benefit?

Volume 59, Issue 4, Pages (April 2011)

The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance.

Volume 66, Issue 1, Pages (July 2014)

Volume 74, Issue 6, Pages (December 2018)

Axel Heidenreich European Urology Supplements

Volume 53, Issue 6, Pages (June 2008)

Volume 67, Issue 4, Pages (April 2015)

Pulmonary Resection for Metastases from Colorectal Cancer

Axel Heidenreich European Urology Supplements

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Volume 69, Issue 4, Pages (April 2016)

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Volume 70, Issue 4, Pages 668-674 (October 2016) Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort Louise Dickinson, Manit Arya, Naveed Afzal, Paul Cathcart, Susan C. Charman, Andrew Cornaby, Richard G. Hindley, Henry Lewi, Neil McCartan, Caroline M. Moore, Senthil Nathan, Chris Ogden, Raj Persad, Jan van der Meulen, Shraddha Weir, Mark Emberton, Hashim U. Ahmed European Urology Volume 70, Issue 4, Pages 668-674 (October 2016) DOI: 10.1016/j.eururo.2016.02.054 Copyright © 2016 Terms and Conditions

Fig. 1 Kaplan-Meier curves demonstrating (A) primary composite disease control in men undergoing whole-gland high-intensity focused ultrasound (HIFU) for prostate cancer in the UK. No transition to any of local salvage therapy (surgery or radiotherapy), systemic therapy, metastases or prostate cancer-specific mortality. (B) Kaplan-Meier curves demonstrating primary composite disease control by National Comprehensive Cancer Network risk groups in men undergoing whole-gland HIFU for prostate cancer in the UK (defined as no transition to any of local salvage therapy [surgery or radiotherapy], systemic therapy, metastases, or prostate cancer-specific mortality). CI=confidence interval. European Urology 2016 70, 668-674DOI: (10.1016/j.eururo.2016.02.054) Copyright © 2016 Terms and Conditions

Fig. 2 Kaplan-Meier curves demonstrating (A) overall biochemical disease-free survival (Stuttgart criteria) in men undergoing whole-gland high-intensity focused ultrasound (HIFU) for prostate cancer in the UK and (B) demonstrating biochemical disease-free survival (Stuttgart criteria) by National Comprehensive Cancer Network risk group in men undergoing whole-gland HIFU for prostate cancer in the UK. CI=confidence interval. European Urology 2016 70, 668-674DOI: (10.1016/j.eururo.2016.02.054) Copyright © 2016 Terms and Conditions

Fig. 3 Kaplan-Meier curves demonstrating (A) overall biochemical disease-free survival (Phoenix criteria) in men undergoing whole-gland high-intensity focused ultrasound (HIFU) for prostate cancer in the UK and (B) demonstrating biochemical disease-free survival (Phoenix criteria) by National Comprehensive Cancer Network risk group in men undergoing whole-gland HIFU for prostate cancer in the UK. CI=confidence interval. European Urology 2016 70, 668-674DOI: (10.1016/j.eururo.2016.02.054) Copyright © 2016 Terms and Conditions